Sanford C. Bernstein Lowers Pacific Biosciences of Californi

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its target price reduced by Sanford C. Bernstein from $9.00 to $2.50 in a report released on Thursday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. A number of other research firms have also weighed in on PACB. Scotiabank cut […]

Related Keywords

California , United States , Sanfordc Bernstein , Oene Mark Van , Davidw Meline , Pacific Biosciences , California Company Profile , Comerica Bank , Securities Exchange Commission , California Inc , Kayne Anderson Rudnick Investment Management , Goldman Sachs Group , Scotiabank , Fairfield Bush , Free Report , California Price , Get Free Report , Director David , Exchange Commission , Investors Weigh In On Pacific Biosciences , Financial Advisors , California Company , California Daily ,